HGF and glioblastoma: In a multicenter phase II randomized, double-blind, placebo-controlled study of onartuzumab plus bevacizumab versus placebo plus bevacizumab in patients with recurrent GBM, combination therapy was beneficial for patients who presented with HGF overexpression or unmethylated O6-methylguanine-DNA methyltransferase (Cloughesy et al., 2017).